Fatigue and quality of life in patients with arterial hypertention: effectiveness of meldonium

  • T. M. Solomenchuk Lviv National Medical University named after Danylo Galytsky
  • L. M. Kopchak Lviv National Medical University named after Danylo Galytsky
  • G. V. Tshngryan Lviv National Medical University named after Danylo Galytsky
Keywords: arterial hypertension, fatigue, quality of life, MFI-20, SF-36, meldonium

Abstract

The aim of the study was to investigate the influence of meldonium (Trizipine® Long) on the health-related quality of life (HRQL) and fatigue in patients with arterial hypertension (AH). A total of 49 hypertensive outpatients with fatigue, 20 male (40.8 %) and 29 female (59.2 %) were examined. The study did not involve patients with concomitant diseases, symptom of which is fatigue. Participants were divided into 2 groups. Twenty-five patients (group 1) received antihypertensive treatment according to the guidelines of the European Society of Cardiology (ESC, 2013). Twenty-four patients (group 2) received antihypertensive treatment with the addition of 1000 mg of meldonium once a day for 8 weeks. The examination included routine clinical, laboratory, and instrumental investigations, including ambulatory blood pressure monitoring (ABPM). The Multidimensional Fatigue Inventory (MFI-20) questionnaire was used to assess the presence and severity of fatigue. The HRQL was assessed by 36-Item Short-Form Health Survey test (SF-36.) The results were evaluated at first appointment and after 8 weeks of treatment. Almost all the patients suffered from moderate fatigue in two subscales: General Fatigue and Physical Fatigue, according to MFI-20 test. In hypertensive patients suffering from fatigue, with poor blood pressure control, we found a significant decrease of HROL. It has been shown that the use of antihypertensive therapy with the addition of meldonium results in significant reduction in fatigue and improving of HRQL as well as improving of the ABPM main data.

Downloads

Download data is not yet available.

References

1. Burchins'kij S. G. Nootropi u farmakoterapії astenonevrotichnih stanіv // Medicina svіtu. – 2004. – T. XVII, № 6. – C. 466–470.
2. Vlasova A. V. Lyamina N. P. Kachestvo zhizni i faktory ego opredelyayushchie u bol'nyh s hronicheskoj serdechnoj nedostatochnost'yu, razvivshejsya posle perenesennogo infarkta miokarda // Serdechnaya nedostatochnost'. – 2002. – № 5. – S. 226–228.
3. Gordeev I. G,. Luchinkina E. E., Hegaj S. V. Korrekciya disfunkcii miokarda u bol'nyh stabil'noj stenokardiej, podvergshihsya koronarnoj revaskulyarizacii, na fone priyoma citoprotektora mildronata // Ros. kardiol. zhurn. – 2009. – Vyp. 76, № 2. – S. 54–58.
4. Zupanec I. A., SHebeko S. K., Otrishko I. A. Znachenie elementov sinergicheskoj politropnosti v mekhanizme realizacii farmakologicheskogo potenciala preparata Kapikor // Therapia. – 2015. – Vyp. 98, № 5. – S. 48–50.
5. Klimenko O. V. Astenіya v zagal'nolіkars'kіj prakticі // Gazeta “Zdorov’ya Ukraїni”. – 2010. – № 18. – C. 21.
6. Kulikova T. Yu. EHffektivnost' i perenosimost' Fenotropila pri terapii astenicheskih rasstojstv nevroticheskogo urovnya // Gaz. “Zdorov’ya Ukraїni”. – 2007. – № 8. – C. 23–24.
7. Mihin V. P., Hlebodarov F. E. Perspektivy primeneniya mildronata u bol'nyh s serdechno-sosudistoj patologiej // Ros. kardiol. zhurn. – 2010. – № 4. – S. 83–92.
8. Solєjko O. Energetichnij zahist mіokarda u hvorih іz hronіchnoyu postіnfarktnoyu anevrizmoyu lіvogo shlunochka // Lіki Ukraїni. – 2004. – № 10. – S. 124–126.
9. Stacenko M. E., Nedogoda S. V., Turkina S. V. i dr. Astenicheskie rasstrojstva u pacientov pozhilogo vozrasta s arterial'noj gipertenziej: vozmozhnosti korrekcii astenii mel'doniem // Rac. farmakoterapiya v kardiologii. – 2013. – Vyp. 9, № 1. – S. 25–30.
10. Unіfіkovanij klіnіchnij protokol pervinnoї, ekstrenoї ta vtorinnoї (specіalіzovanoї) medichnoї dopomogi «Arterіal'na gіpertenzіya» / Nakaz MOZ Ukraуni № 384 vіd 24.05.2012 r. «Pro zatverdzhennya ta vprovadzhennya mediko-tekhnologіchnih dokumentіv zі standartizacії medichnoї dopomogi pri arterіal'nіj gіpertenzії» // http://moz.gov.ua/ua/portal/dn_20120524_384.html.
11. Hlebodarov F. E. Mihin V. P. Rol' citoprotektorov v lechenii bol'nyh arteial'noj gipertoniej na fone terapii ehnalaprilom // Ros. kardiol. zhurn. – 2009. – № 5. – S. 46–50.
12. Chekman I. S., Gorchakova N. A., Francuzova S. B. i dr. Metabolitnye i metabolitotropnye preparaty v sisteme kardio- i organoprotekcii. – K., 2009. – 155 s.
13. Ariza-Solé A., Formiga F., Vidán M.T. et al. Impact of frailty and functional status on outcomes in elderly patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: rationale and design of the IFFANIAM Study // Clin. Cardiology. – 2013. – Vol. 36, N 10. – P. 565–569.
14. Dzerve V. MILSS I Study Group. A dose-dependent improvement in exercise tolerance in patients with stable angina treated with mildronate: a clinical trial “MILSS I” // Medicina (Kaunas). – 2011. – Vol. 47, N 10. – Р. 544–551.
15. http://list.wada-ama.org/list/s4-hormone-and-metabolic-modulators/
16. Konerman M., Weeks K. R., Shands J. R. Short Form (SF-36) Health Survey measures are associated with decreased adherence among urban african americans with severe, poorly controlled hypertension // J. Clin. Hypertens. – 2011. – Vol. 13. – P. 385–390.
17. Lambert G. W., Hering D., Esler M. D. et al. Health-related quality of life after renal denervation in patients with treatment-resistant hypertension // Hypertension. – 2012. – Vol. 60. – P. 1479–1484.
18. Liang X.-Y., Nie S.-F., Qu K.-Y. et al. Evaluation of health-related quality of life among hypertensive patients in a rural area, PR China // J. of Human Hypertension. – 2006. – Vol. 20. – P. 227–229.
19. Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertens. – 2013. – Vol. 31, N 7. – P. 1281–1357.
20. Mizuno K., Tanaka M., Nozaki S. et al. Antifatigue effects of coenzyme Q10 during physical fatigue // Nutrition. – 2008. – Vol. 24, N 4. – P. 293–299.
21. Myhill S., Booth N. E., Mac Laren-Howard J. et. al. Chronic fatigue syndrome and mitochondrial dysfunction // International Journal of Clinical and Experimental Medicine. – 2009. – Vol. 2, N 1). – P. 1–16.
22. Plioplys A. V., Plioplys S. Amantadine and L-carnitine treatment of chronic fatigue syndrome // Neuropsychobiology. – 1997. – Vol. 35, N 1. – P. 16–23.
23. Poljičanin T., Ajduković D., Šekerija M. et al. Diabetes mellitus and hypertension have comparable adverse effects on health-related quality of life. // BMC Public Health. – 2010. – Vol. 10, N 1. – P. 12. Published online 2010 January 13. doi: 10.1186/1471-2458-10-12.
24. Shanableh S., Abdulkarem A., Shamssain M. et al. Quality of life of hypertensive patients on different types of antihypertensive medications // IOSR Journal of Pharmacy. – 2014. – Vol. 4 (Issue 5). – P. 23–28.
25. Smets E. M., Garssen B., Bonke B. et al. The Multidimensional Fatigue Inventory (MFI): psychometric qualities of an instrument to assess fatigue // J. Psychosom. Res. – 1995. – Vo l. 39. – P. 315–325.
26. Theodorou M., Kaitelidou D., Galanis P. et al. Quality of life measurement in patients with hypertension in Cyprus // Hellenic J. Cardiol. – 2011. – Vol. 52, N 5. – P. 407–415.
27. Ware J. E., Sherbourne C. D. The MOS 36-item short-form health survey (SF-36): conceptual framework and item selection // Med. Care. – 1992. – Vo l. 30. – P. 473–483.

Abstract views: 158
PDF Downloads: 66
Published
2018-12-05
How to Cite
Solomenchuk, T. M., Kopchak, L. M., & Tshngryan, G. V. (2018). Fatigue and quality of life in patients with arterial hypertention: effectiveness of meldonium. Likarsʹka Sprava, (3-4), 105-114. https://doi.org/10.31640/3-4.2018(16)
Section
Guide lines for the practitioner